June 22, 2018 10:06 AM EDTUpdated 10:19 AM
News Briefing

Nanobi­otix shares rock­et up on a mar­gin­al suc­cess for soft tis­sue sar­co­ma; As­traZeneca wins pi­o­neer­ing PD-L1 OK in In­dia

John Carroll

Editor & Founder

→ Shares of Nanobi­otix (Eu­ronext: NANO) soared af­ter the biotech re­port­ed pos­i­tive though mar­gin­al re­sults for its Phase II/III study of NBTXR3 in

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times